Corona Remedies Limited

Corona Remedies Limited is a pharmaceutical company incorporated in August 2004 and headquartered in Ahmedabad, Gujarat. It develops, manufactures and markets branded formulations across several therapeutic areas, including women's healthcare, cardiology and cardio-diabetic care, pain management and urology, alongside a broader multispecialty portfolio. As of mid-2025 the company sold roughly 70 brands spanning these segments. The business has built a pan-India presence over two decades, supported by a field force of more than 2,600 medical representatives operating across 22 states. Manufacturing is carried out at two facilities in Gujarat and Himachal Pradesh, both certified to EU-GMP and WHO-GMP standards, with a further hormone-focused plant in Gujarat under commissioning. A small in-house research and development team supports its product pipeline. According to CRISIL Intelligence, Corona Remedies has been among the fastest growing companies within the top 30 players in the Indian Pharmaceutical Market by domestic sales in recent years. Its growth has been driven by strong positions in select therapeutic niches such as women's health and pain management, together with a chronic and specialty-heavy product mix that supports healthier margins than the broader acute-therapy market.

Corona Remedies raised approximately Rs 195 crore from anchor investors ahead of its IPO, allotting about 18.3 lakh shares at the Rs 1,062 issue price. Participants included several domestic mutual fund houses such as SBI, ICICI Prudential, Kotak Mahindra, Axis, Mirae Asset, Aditya Birla Sun Life, Invesco, DSP and Franklin India, alongside other institutional investors including SBI Life Insurance and Ashoka India.